CoChat

The role of the microbiome in NAFLD and NASH

Open access

The DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly becoming the most prevalent liver disease worldwide. A sizable minority of NAFLD patients develop nonalcoholic steatohepatitis (NASH), which is characterized by inflammatory changes that can lead to progressive liver damage, cirrhosis, and hepatocellular carcinoma. Recent studies have shown that in addition to genetic predisposition and diet, the gut microbiota affects hepatic carbohydrate and lipid metabolism as well as influences the balance between pro‐inflammatory and anti‐inflammatory effectors in the liver, thereby impacting NAFLD and its progression to NASH. In this review, we will explore the impact of gut microbiota and microbiota‐derived compounds on the development and progression of NAFLD and NASH, and the unexplored factors related to potential microbiome contributions to this common liver disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201809302

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Gut microbiota‐derived compounds affecting liver metabolism Microbiome‐derived compounds affect the hepatocytes via small molecules leading to highly interconnected effects including pro‐inflammatory signaling, changes in gene expression, and alteration in metabolism and toxicity. Bile acids bind their receptor in the intestinal epithelial cells leading to release of βKlotho that travels via portal vein to the liver where it binds FGFR4 on the surface of hepatocytes and leads to changes in metabolism. Bile acids also activate the TGR5 receptor on the Kupffer cells leading to secretion of pro‐inflammatory cytokines that in turn signal to hepatocytes. Bacterial pattern molecules, i.e., peptidoglycan and LPS, signal via TRL2 and TRL4. Short‐chain fatty acids act via binding to their receptors (acetate binds GPR43) and alter metabolism; additionally, butyrate is histone deacetylase (HDAC) inhibitor and regulates gene expression through modulation of chromatin state. Phenylacetate by unknown mechanism affects expression of metabolic genes such as Fasn and Lpl leading to metabolic changes. Finally, acetaldehyde, toxic derivative of ethanol, exacerbates high oxidative stress on the hepatocytes.
Figure 1 Gut microbiota‐derived compounds affecting liver metabolism Microbiome‐derived compounds affect the hepatocytes via small molecules leading to highly interconnected effects including pro‐inflammatory signaling, changes in gene expression, and alteration in metabolism and toxicity. Bile acids bind their receptor in the intestinal epithelial cells leading to release of βKlotho that travels via portal vein to the liver where it binds FGFR4 on the surface of hepatocytes and leads to changes in metabolism. Bile acids also activate the TGR5 receptor on the Kupffer cells leading to secretion of pro‐inflammatory cytokines that in turn signal to hepatocytes. Bacterial pattern molecules, i.e., peptidoglycan and LPS, signal via TRL2 and TRL4. Short‐chain fatty acids act via binding to their receptors (acetate binds GPR43) and alter metabolism; additionally, butyrate is histone deacetylase (HDAC) inhibitor and regulates gene expression through modulation of chromatin state. Phenylacetate by unknown mechanism affects expression of metabolic genes such as Fasn and Lpl leading to metabolic changes. Finally, acetaldehyde, toxic derivative of ethanol, exacerbates high oxidative stress on the hepatocytes.CC BY · PubMed Central
Figure 2 Pattern diagram featuring gut permeability, bacterial translocation, and TLR signaling in NAFLD/NASH Gut microbiota alteration might contribute to increased gut permeability, translocation of bacteria, and microbiota products from the gut to liver through the portal vein. Different TLRs (TLR4, TLR9, TLR2, TLR5) in different cell types of the liver (Kupffer cells, hepatic stellate cells, hepatocytes) sense bacterial products and trigger downstream inflammatory responses as well as cytokine production. Different cell types, such as Kupffer cells and hepatic stellate cells, might interact with each other in inducing inflammation and fibrosis.
Figure 2 Pattern diagram featuring gut permeability, bacterial translocation, and TLR signaling in NAFLD/NASH Gut microbiota alteration might contribute to increased gut permeability, translocation of bacteria, and microbiota products from the gut to liver through the portal vein. Different TLRs (TLR4, TLR9, TLR2, TLR5) in different cell types of the liver (Kupffer cells, hepatic stellate cells, hepatocytes) sense bacterial products and trigger downstream inflammatory responses as well as cytokine production. Different cell types, such as Kupffer cells and hepatic stellate cells, might interact with each other in inducing inflammation and fibrosis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Ackermann D, Schutze H (1910) The formation of trimethylamine by bacterium prodigiosum. Zentralb Physiol 24: 210–211

Cited by

See all 548

Metadata

Authors
Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E.
Affiliations
  • Weizmann Institute of Science (IL)
  • The First Affiliated Hospital, Sun Yat-sen University (CN)
  • Tel Aviv Sourasky Medical Center (IL)
Corresponding author
Elinav, Eran
Venue
EMBO Molecular Medicine
Published
2018-12-27
Volume
11
Issue
2
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2907493655
Cited by
523
References
125
Citations by year
2026: 30 · 2025: 63 · 2024: 73 · 2023: 94 · 2022: 91 · 2021: 76 · 2020: 71 · 2019: 25
FWCI
4.22
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • European Union's Horizon 2020 (747114)
  • European Crohn's and Colitis Organization (ECCO) Fellowship
  • Ke Lin Program of the First Affiliated Hospital of Sun Yat‐sen University
  • Alexander Grass foundation
  • Y. and R. Ungar
  • Gurwin Family Fund for Scientific Research
  • Crown Endowment Fund for Immunological Research
  • Else Kroener‐Fresenius Foundation
  • Benoziyo Endowment Fund for the Advancement of Science
  • Adelis Foundation
  • French National Center for Scientific Research
  • European Research Council
  • Marie Curie Integration grant
  • Rising Tide Foundation
  • Helmholtz Foundation
  • Canadian Institute of Advanced Research
  • The Bill & Melinda Gates Foundation & Howard Hughes Medical Institute
  • Abisch‐Frenkel Foundation for the Promotion of Life Sciences
  • Leona M. and Harry B. Helmsley Charitable Trust
  • German–Israeli Foundation for Scientific Research and Development
  • Israel Science Foundation
  • Minerva Foundation
  • European Foundation for the Study of Diabetes
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, gut microbiota, microbiome, cardiometabolic syndrome, obesity, diabetes mellitus, dyslipidemia, hepatic lipid metabolism, hepatic carbohydrate metabolism, inflammation, gut microbiota metabolites, liver cirrhosis, hepatocellular carcinoma
MeSH terms
Gastrointestinal Microbiome, Bacteria, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Disease Progression, Carbohydrate Metabolism, Lipid Metabolism, Microbiota, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.